450,506 results on '"Chemotherapy"'
Search Results
2. Serpentine supravenous hyperpigmentation induced by chemotherapy: a systematic review.
- Author
-
Shan, Judy, Obiakor, Bianca, Cheng, Justin, Francois, Rony, and Dobry, Allison
- Subjects
Chemotherapy ,Dermatooncology ,Infusion reaction ,Skin hyperpigmentation ,Supravenous serpentine hyperpigmentation ,Humans ,Hyperpigmentation ,Antineoplastic Agents ,Skin Pigmentation ,Skin ,Erythema - Abstract
Serpentine supravenous hyperpigmentation (SSH) describes increased skin pigmentation that develops in the area immediately overlying the vessels through which chemotherapeutic drugs are administered. While SSH can be cosmetically distressing and there are no definitive management options, the literature is severely limited and the variations in clinical presentation, risk factors, and histopathology of SSH across patients are not well understood. We aimed to systematically summarize characteristics from current available data, and thus improve SSH awareness and management. A literature search was conducted in PubMed using specific eligibility criteria through the end of December 2022. Included articles focused on patients who experienced SSH after chemotherapy infusion. Study quality was assessed using a modified Oxford Centre for Evidence-Based Medicine quality rating scheme. Of the 41 articles identified by literature search, 24 met eligibility criteria. Two additional articles were identified through the reference sections of retrieved articles, for 26 articles total. All articles were case reports, representing 28 patients total. Locations of SSH were mostly in the forearm near the site of injection (85%), and the most common associated symptom was erythema. Histopathologic analysis was available for half of cases, the majority of which were inflammatory in nature. The most common inflammatory pattern observed was a vacuolar/lichenoid interface dermatitis. Duration of SSH ranged from days to > 1 year after the chemotherapy was stopped. Six (21%) patients were managed with topical steroids and oral vasodilators, six (21%) patients switched to central venous infusion rather than peripheral infusion, five (18%) patients received only supportive care, three (11%) patients received venous washing with chemotherapy, three (11%) patients stopped chemotherapy, and one (4%) patient reduced the chemotherapy dosage. Ten (36%) patients attained complete resolution, seven (25%) had SSH that was near resolution/fading, and three (11%) had persistent hyperpigmentation. Although SSH often spontaneously resolves once the chemotherapeutic agent is stopped, it can persist in some patients and cause significant distress. As the literature is severely limited and there are no definitive treatments, additional research using more standardized definitions and methods of assessments is necessary to improve characterization of SSH and evaluate potential interventions.
- Published
- 2024
3. Light-Chain Cardiac Amyloidosis: Cardiac Magnetic Resonance for Assessing Response to Chemotherapy.
- Author
-
Guo, Yubo, Li, Xiao, Gao, Yajuan, Shen, Kaini, Lin, Lu, Wang, Jian, Cao, Jian, Wan, Ke, Zhou, Xi, Chen, Yucheng, Zhang, Long, Li, Jian, Wang, Yining, and Zhang, Zhuoli
- Subjects
Amyloidosis ,Cardiac magnetic resonance ,Chemotherapy ,Longitudinal strain ,Tissue characterization ,Humans ,Male ,Middle Aged ,Female ,Prospective Studies ,Cardiomyopathies ,Magnetic Resonance Imaging ,Feasibility Studies ,Amyloidosis ,Immunoglobulin Light-chain Amyloidosis ,Treatment Outcome ,Magnetic Resonance Imaging ,Cine ,Antineoplastic Agents - Abstract
OBJECTIVE: Cardiac magnetic resonance (CMR) is a diagnostic tool that provides precise and reproducible information about cardiac structure, function, and tissue characterization, aiding in the monitoring of chemotherapy response in patients with light-chain cardiac amyloidosis (AL-CA). This study aimed to evaluate the feasibility of CMR in monitoring responses to chemotherapy in patients with AL-CA. MATERIALS AND METHODS: In this prospective study, we enrolled 111 patients with AL-CA (50.5% male; median age, 54 [interquartile range, 49-63] years). Patients underwent longitudinal monitoring using biomarkers and CMR imaging. At follow-up after chemotherapy, patients were categorized into superior and inferior response groups based on their hematological and cardiac laboratory responses to chemotherapy. Changes in CMR findings across therapies and differences between response groups were analyzed. RESULTS: Following chemotherapy (before vs. after), there were significant increases in myocardial T2 (43.6 ± 3.5 ms vs. 44.6 ± 4.1 ms; P = 0.008), recovery in right ventricular (RV) longitudinal strain (median of -9.6% vs. -11.7%; P = 0.031), and decrease in RV extracellular volume fraction (ECV) (median of 53.9% vs. 51.6%; P = 0.048). These changes were more pronounced in the superior-response group. Patients with superior cardiac laboratory response showed significantly greater reductions in RV ECV (-2.9% [interquartile range, -8.7%-1.1%] vs. 1.7% [-5.5%-7.1%]; P = 0.017) and left ventricular ECV (-2.0% [-6.0%-1.3%] vs. 2.0% [-3.0%-5.0%]; P = 0.01) compared with those with inferior response. CONCLUSION: Cardiac amyloid deposition can regress following chemotherapy in patients with AL-CA, particularly showing more prominent regression, possibly earlier, in the RV. CMR emerges as an effective tool for monitoring associated tissue characteristics and ventricular functional recovery in patients with AL-CA undergoing chemotherapy, thereby supporting its utility in treatment response assessment.
- Published
- 2024
4. Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Mutation Profile and Disease Aggressiveness.
- Author
-
Perrier, Nancy, Brown, Spandana, Holla, Vijaykumar, Dadu, Ramona, Busaidy, Naifa, Sherman, Steven, Cabanillas, Maria, Waguespack, Steven, Zafereo, Mark, Grubbs, Elizabeth, Shirali, Aditya, Hu, Mimi, Chiang, Yi-Ju, Graham, Paul, Fisher, Sarah, and Sosa, Julie Ann
- Subjects
chemotherapy ,clinical outcomes ,molecular testing ,next-generation sequencing ,somatic mutation ,survival - Abstract
CONTEXT: Next-generation sequencing (NGS) analysis of sporadic medullary thyroid carcinoma (sMTC) has led to increased detection of somatic mutations, including RET M918T, which has been considered a negative prognostic indicator. OBJECTIVE: This study aimed to determine the association between clinicopathologic behavior and somatic mutation identified on clinically motivated NGS. METHODS: In this retrospective cohort study, patients with sMTC who underwent NGS to identify somatic mutations for treatment planning were identified. Clinicopathologic factors, time to distant metastatic disease (DMD), disease-specific survival (DSS), and overall survival (OS) were compared between somatic mutations. RESULTS: Somatic mutations were identified in 191 sMTC tumors, including RET M918T (53.4%), other RET codons (10.5%), RAS (18.3%), somatic RET indels (8.9%), and RET/RAS wild-type (WT) status (8.9%). The median age at diagnosis was 50 years (range, 11-83); 46.1% were female. When comparing patients with RET M918T, RET-Other, and RET WT (which included RAS and RET/RAS WT), there were no differences in sex, TNM category, systemic therapy use, time to DMD, DSS, or OS. On multivariate analysis, older age at diagnosis (HR 1.05, P < .001; HR 1.06, P< .001) and M1 stage at diagnosis (HR 3.17, P = .001; HR 2.98, P = .001) were associated with decreased DSS and OS, respectively, but mutation cohort was not. When comparing RET M918T to RET indels there was no significant difference in time to DMD, DSS, or OS between the groups. CONCLUSION: Somatic RET mutations do not portend compromised DSS or OS in a cohort of sMTC patients who underwent clinically motivated NGS.
- Published
- 2024
5. Challenges and prospective of enhancing hydatid cyst chemotherapy by nanotechnology and the future of nanobiosensors for diagnosis
- Author
-
Sadr, Soheil, Lotfalizadeh, Narges, Abbasi, Amir Mohammad, Soleymani, Nooshinmehr, Hajjafari, Ashkan, Moghadam, Elahe Roohbaksh Amooli, and Borji, Hassan
- Published
- 2023
6. Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
- Author
-
XIN WANG, Principal Investigator
- Published
- 2024
7. ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer (ADARNAT)
- Author
-
Amparo Garcia-Tejedor, Principal Investigator
- Published
- 2024
8. Acupuncture for Insomnia in Breast Cancer Patients Undergoing Chemotherapy (BCI)
- Author
-
Prof. Zhang Zhang-Jin, Professor
- Published
- 2024
9. Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
- Author
-
XIN WANG, Principal Investigator
- Published
- 2024
10. Correlation of Timing of Pegfilgrastim Administration and PIBP.
- Author
-
Kun Wang, professor
- Published
- 2024
11. Effect of Alpha Lipoic Acid on Chemotherapy Induced Neurological Changes in Breast Cancer Patients
- Author
-
Dar EL Salam Cancer Hospital and Shaimaa Mohamed SafaaElDin, Pharmacist
- Published
- 2024
12. Breast Cancer - Navigate - Prospective Cohort
- Author
-
The Chrysalis Initiative and Betina Yanez, Associate Professor
- Published
- 2024
13. The SaVe Project-Sarcopenia and Vertigo in Aging Patients With Colorectal Cancer (SaVe)
- Author
-
Copenhagen University Hospital - Rigshospitalet, Department of Occupational Therapy and Physiotherapy, Copenhagen University Hospital - Herlev and Gentofte Hospital, Department of Medicine, Copenhagen University Hospital - Herlev and Gentofte Hospital, Department of Oncology, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Odense University Hospital, Department of Geriatric Medicine, Copenhagen University Hospital - Amager and Hvidovre Hospital, and Jan Christensen, Senior researcher, Head of research
- Published
- 2024
14. Hypoglossal Acupuncture for Dysgeusia in Patients Undergoing Chemotherapy (OralAcu)
- Author
-
Heidemarie Haller, Postdoctoral Research Fellow
- Published
- 2024
15. Outcomes of neoadjuvant chemotherapy and radical hysterectomy for locally advanced cervical cancer at Kigali University Teaching Hospital, Rwanda: a retrospective descriptive study.
- Author
-
Ntasumbumuyange, Diomede, Magriples, Urania, George, Jessica, Grover, Surbhi, Bazzett-Matabele, Lisa, Ngabonziza, Eugene, Ghebre, Rahel, and DeBoer, Rebecca
- Subjects
Cervical cancer ,Limited resources ,Neoadjuvant chemotherapy ,Radical hysterectomy ,Humans ,Female ,Middle Aged ,Uterine Cervical Neoplasms ,Neoadjuvant Therapy ,Retrospective Studies ,Carcinoma ,Squamous Cell ,Rwanda ,Universities ,Hospitals ,Teaching ,Neoplasm Staging ,Hysterectomy ,Antineoplastic Combined Chemotherapy Protocols ,Chemotherapy ,Adjuvant - Abstract
BACKGROUND: Half of countries in Africa lack access to radiation (RT), which is essential for standard treatment of locally advanced cervical cancers. We evaluated outcomes for patients treated with neoadjuvant chemotherapy (NACT) followed by radical hysterectomy in settings where no RT is available. METHODS: We performed a retrospective descriptive study of all patients with FIGO stage IB2-IIA2 and some exceptional stage IIB cases who received NACT and surgery at Kigali University Teaching Hospital in Rwanda. Patients were treated with NACT consisting of carboplatin and paclitaxel once every 3 weeks for 3-4 cycles before radical hysterectomy. We calculated recurrence rates and overall survival (OS) rate was determined by Kaplan-Meier estimates. RESULTS: Between May 2016 and October 2018, 57 patients underwent NACT and 43 (75.4%) were candidates for radical hysterectomy after clinical response assessment. Among the 43 patients who received NACT and surgery, the median age was 56 years, 14% were HIV positive, and FIGO stage distribution was: IB2 (32.6%), IIA1 (7.0%), IIA2 (51.2%) and IIB (9.3%). Thirty-nine (96%) patients received 3 cycles and 4 (4%) received 4 cycles of NACT. Thirty-eight (88.4%) patients underwent radical hysterectomy as planned and 5 (11.6%) had surgery aborted due to grossly metastatic disease. Two patients were lost to follow up after surgery and excluded from survival analysis. For the remaining 41 patients with median follow-up time of 34.4 months, 32 (78%) were alive with no evidence of recurrence, and 8 (20%) were alive with recurrence. One patient died of an unrelated cancer. The 3-year OS rate for the 41 patients who underwent NACT and surgery was 80.8% with a recurrence rate of 20%. CONCLUSIONS: Neoadjuvant chemotherapy with radical hysterectomy is a feasible treatment option for locally advanced cervical cancer in settings with limited access to RT. With an increase in gynecologic oncologists skilled at radical surgery, this approach may be a more widely available alternative treatment option in countries without radiation facilities.
- Published
- 2024
16. The FBXW7-binding sites on FAM83D are potential targets for cancer therapy.
- Author
-
Jiang, Xiaoyu, Wang, Yuli, Guo, Lulu, Wang, Yige, Miao, Tianshu, Ma, Lijuan, Wei, Qin, Lin, Xiaoyan, Mao, Jian-Hua, and Zhang, Pengju
- Subjects
Breast cancer ,Chemotherapy ,FAM83D ,FBXW7 ,Metastasis ,Ubiquitination and degradation ,Humans ,Female ,F-Box-WD Repeat-Containing Protein 7 ,Cell Cycle Proteins ,Cell Line ,Tumor ,Breast Neoplasms ,Prognosis ,Cell Proliferation ,Gene Expression Regulation ,Neoplastic ,Microtubule-Associated Proteins - Abstract
Increasing evidence shows the oncogenic function of FAM83D in human cancer, but how FAM83D exerts its oncogenic function remains largely unclear. Here, we investigated the importance of FAM83D/FBXW7 interaction in breast cancer (BC). We systematically mapped the FBXW7-binding sites on FAM83D through a comprehensive mutational analysis together with co-immunoprecipitation assay. Mutations at the FBXW7-binding sites on FAM83D led to that FAM83D lost its capability to promote the ubiquitination and proteasomal degradation of FBXW7; cell proliferation, migration, and invasion in vitro; and tumor growth and metastasis in vivo, indicating that the FBXW7-binding sites on FAM83D are essential for its oncogenic functions. A meta-evaluation of FAM83D revealed that the prognostic impact of FAM83D was independent on molecular subtypes. The higher expression of FAM83D has poorer prognosis. Moreover, high expression of FAM83D confers resistance to chemotherapy in BCs, which is experimentally validated in vitro. We conclude that identification of FBXW7-binding sites on FAM83D not only reveals the importance for FAM83D oncogenic function, but also provides valuable insights for drug target.
- Published
- 2024
17. Stability and consistency of symptom clusters in younger versus older patients receiving chemotherapy.
- Author
-
Morse, Lisa, Cooper, Bruce, Ritchie, Christine, Wong, Melisa, Harris, Carolyn, Shin, Joosun, Oppegaard, Kate, Hammer, Marilyn, Schimmel, Alejandra, Paul, Steven, Conley, Yvette, Levine, Jon, Miaskowski, Christine, and Kober, Kord
- Subjects
Cancer ,Chemotherapy ,Exploratory factor analysis ,Older adults ,Patient reported outcomes ,Symptom clusters ,Symptoms ,Humans ,Aged ,Antineoplastic Agents ,Syndrome ,Severity of Illness Index ,Longitudinal Studies ,Neoplasms - Abstract
BACKGROUND: By 2035, the number of newly diagnosed cancer cases will double and over 50% will be in older adults. Given this rapidly growing demographic, a need exists to understand how age influences oncology patients symptom burden. The study purposes were to evaluate for differences in the occurrence, severity, and distress of 38 symptoms in younger (
- Published
- 2024
18. Common and distinct risk factors that influence more severe and distressing shortness of breath profiles in oncology outpatients.
- Author
-
Shin, Joosun, Hammer, Marilyn, Cooley, Mary, Cooper, Bruce, Paul, Steven, Cartwright, Frances, Kober, Kord, Conley, Yvette, Levine, Jon, and Miaskowski, Christine
- Subjects
cancer ,chemotherapy ,distress ,dyspnea ,shortness of breath - Abstract
BACKGROUND: Shortness of breath occurs in 10%-70% of oncology patients. Very little is known about interindividual variability in its severity and distress and associated risk factors. Using latent profile analyses (LPAs), purpose was to identify subgroups of patients with distinct severity and distress profiles for shortness of breath as single symptom dimensions. In addition, a joint LPA was done using patients severity AND distress ratings. For each of the three LPAs, differences among the shortness of breath classes in demographic, clinical, symptom, stress, and resilience characteristics were evaluated. METHODS: Patients completed ratings of severity and distress from shortness of breath a total of six times over two cycles of chemotherapy. All of the other measures were completed at enrollment (i.e., prior to the second or third cycle of chemotherapy). Separate LPAs were done using ratings of severity and distress, as well as a joint analysis using severity AND distress ratings. Differences among the latent classes were evaluated using parametric and nonparametric tests. RESULTS: For severity, two classes were identified (Slight to Moderate [91.6%] and Moderate to Severe [8.4%]). For distress, two classes were identified (A Little Bit to Somewhat [83.9%] and Somewhat to Quite a Bit [16.1%]). For the joint LPA, two classes were identified (Lower Severity and Distress [79.9%] and Higher Severity and Distress [20.1%]). While distinct risk factors were associated with each of the LPAs, across the three LPAs, the common risk factors associated with membership in the worse class included: a past or current history of smoking, poorer functional status, and higher comorbidity burden. In addition, these patients had a higher symptom burden and higher levels of cancer-specific stress. CONCLUSIONS: Clinicians can use the information provided in this study to identify high-risk patients and develop individualized interventions.
- Published
- 2024
19. Prediction of gastrointestinal symptoms trajectories using omega-3 and inflammatory biomarkers in early-stage breast cancer patients receiving chemotherapy.
- Author
-
Arcos, Daniela, Ng, Ding, Ke, Yu, Toh, Yi, and Chan, Alexandre
- Subjects
Breast cancer ,Chemotherapy ,Gastrointestinal symptoms ,Inflammation ,Omega-3 ,Humans ,Female ,Breast Neoplasms ,Interleukin-8 ,Quality of Life ,Prospective Studies ,Gastrointestinal Diseases ,Biomarkers ,Surveys and Questionnaires - Abstract
PURPOSE: Gastrointestinal (GI) symptoms are common among breast cancer patients undergoing chemotherapy, negatively impacting treatment outcomes and quality of life. Evidence points to inflammatory processes as the underlying cause of chemotherapy-associated GI symptoms. Relatedly, omega-3 (n-3) has been linked to anti-inflammatory processes. The primary objective of this study was to examine the associations between baseline n-3, baseline inflammatory markers and GI symptom progression in early-stage breast cancer patients receiving chemotherapy. METHODS: In this secondary analysis of a prospective cohort study, we analyzed baseline levels of inflammatory biomarkers (measured using a Luminex bead-immunoassay) and plasma levels of DHA, EPA, and FFA (measured using enzyme-linked immunosorbent assay). GI symptoms were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire in Cancer Patients (EORTC QLQ-C30) symptom scale scores at baseline (T1) and at least 6 weeks after, during chemotherapy (T2). Inferential statistics were used to analyze associations between the variables of interest. RESULTS: The analysis included 31 female breast cancer patients (mean age ± SD = 50.5 ± 8.8; 89.6% receiving anthracycline-based chemotherapy). Higher levels of docosahexaenoic acid (DHA) and interleukin-8 (IL-8) predicted increases in appetite loss. Similarly, higher IL-8 predicted worsened nausea and vomiting. CONCLUSION: Baseline IL-8 and DHA predicted GI symptom progression in early-stage breast cancer patients undergoing chemotherapy. Future studies are required to evaluate how therapeutic intervention targeting these biomarkers may mitigate gastrointestinal symptoms in cancer patients.
- Published
- 2024
20. Pharmacologic interventions for the treatment of equine herpesvirus-1 in domesticated horses: A systematic review.
- Author
-
Goehring, Lutz, Dorman, David, Osterrieder, Klaus, Burgess, Brandy, Dougherty, Kelsie, Gross, Peggy, Neinast, Claire, Pusterla, Nicola, Soboll-Hussey, Gisela, and Lunn, David
- Subjects
chemotherapy ,equine ,equine herpesvirus myeloencephalopathy ,herpesvirus‐1 ,Animals ,Horses ,Herpesvirus 1 ,Equid ,Horse Diseases ,Herpesviridae Infections ,Antiviral Agents ,Valacyclovir - Abstract
BACKGROUND: Equine herpes virus type 1 (EHV-1) infection in horses is associated with upper respiratory disease, neurological disease, abortions, and neonatal death. REVIEW QUESTION: Does pharmacological therapy decrease either the incidence or severity of disease or infection caused by EHV-1 in domesticated horses? METHODS: A systematic review was preformed searching AGRICOLA, CAB Abstracts, Cochrane, PubMed, Web of Science, and WHO Global Health Index Medicus Regional Databases to identify articles published before February 15, 2021. Selection criteria were original research reports published in peer reviewed journals, and studies investigating in vivo use of therapeutic agents for prevention or treatment of EHV-1 in horses. Outcomes assessed included measures related to clinical outcomes that reflect symptomatic EHV-1 infection or virus infection. We evaluated risk of bias and performed a GRADE evaluation of the quality of evidence for interventions. RESULTS: A total of 7009 unique studies were identified, of which 9 met the inclusion criteria. Two studies evaluated valacyclovir or small interfering RNAs, and single studies evaluated the use of a Parapoxvirus ovis-based immunomodulator, human alpha interferon, an herbal supplement, a cytosine analog, and heparin. The level of evidence ranged between randomized controlled studies and observational trials. The risk of bias was moderate to high and sample sizes were small. Most studies reported either no benefit or minimal efficacy of the intervention tested. CONCLUSIONS AND CLINICAL IMPORTANCE: Our review indicates minimal or limited benefit either as a prophylactic or post-exposure treatment for any of the studied interventions in the mitigation of EHV-1-associated disease outcome.
- Published
- 2024
21. EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer
- Author
-
Chan, Ann M, Aguirre, Brian, Liu, Lucia, Mah, Vei, Balko, Justin M, Tsui, Jessica, Wadehra, Navin P, Moatamed, Neda A, Khoshchehreh, Mahdi, Dillard, Christen M, Kiyohara, Meagan, Elshimali, Yahya, Chang, Helena R, Marquez-Garban, Diana, Hamilton, Nalo, Pietras, Richard J, Gordon, Lynn K, and Wadehra, Madhuri
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Immunology ,Clinical Research ,Cancer ,Breast Cancer ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,triple-negative breast cancer ,chemotherapy ,epithelial membrane protein 2 ,biomarker ,Oncology and carcinogenesis - Abstract
Breast cancer (BC) remains among the most commonly diagnosed cancers in women worldwide. Triple-negative BC (TNBC) is a subset of BC characterized by aggressive behavior, a high risk of distant recurrence, and poor overall survival rates. Chemotherapy is the backbone for treatment in patients with TNBC, but outcomes remain poor compared to other BC subtypes, in part due to the lack of recognized functional targets. In this study, the expression of the tetraspan protein epithelial membrane protein 2 (EMP2) was explored as a predictor of TNBC response to standard chemotherapy. We demonstrate that EMP2 functions as a prognostic biomarker for patients treated with taxane-based chemotherapy, with high expression at both transcriptomic and protein levels following treatment correlating with poor overall survival. Moreover, we show that targeting EMP2 in combination with docetaxel reduces tumor load in syngeneic and xenograft models of TNBC. These results provide support for the prognostic and therapeutic potential of this tetraspan protein, suggesting that anti-EMP2 therapy may be beneficial for the treatment of select chemotherapy-resistant TNBC tumors.
- Published
- 2024
22. A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer.
- Author
-
Gumusay, Ozge, Huppert, Laura, Magbanua, Mark, Wabl, Chiara, Assefa, Michael, Chien, Amy, Melisko, Michelle, Majure, Melanie, Moasser, Mark, Park, John, and Rugo, Hope
- Subjects
Chemotherapy ,Cyclophosphamide ,Eribulin ,Metastatic breast cancer ,Humans ,Adult ,Middle Aged ,Aged ,Aged ,80 and over ,Female ,Breast Neoplasms ,Receptor ,ErbB-2 ,Cyclophosphamide ,Ketones ,Furans ,Triple Negative Breast Neoplasms ,Neutropenia ,Antineoplastic Combined Chemotherapy Protocols ,Treatment Outcome ,Polyether Polyketides - Abstract
PURPOSE: We hypothesized that eribulin combined with cyclophosphamide (EC) would be an effective combination with tolerable toxicity for the treatment of advanced breast cancer (ABC). METHODS: Patients with histologically confirmed metastatic or unresectable ABC with any number of prior lines of therapy were eligible to enroll. In the dose escalation cohort, dose level 0 was defined as eribulin 1.1 mg/m2 and cyclophosphamide 600 mg/m2, and dose level 1 was defined as eribulin 1.4 mg/m2 and cyclophosphamide 600 mg/m2. Eribulin was given on days 1 and 8 and cyclophosphamide on day 1 of a 21-day cycle. In the dose expansion cohort, enrollment was expanded at dose level 1. The primary objective was clinical benefit rate (CBR), and secondary objectives were response rate (RR), duration of response (DOR), progression-free survival (PFS), and safety. RESULTS: No dose-limiting toxicities were identified in the dose escalation cohort (n = 6). In the dose expansion cohort, an additional 38 patients were enrolled for a total of 44 patients, including 31 patients (70.4%) with hormone receptor-positive (HR +)/HER2- disease, 12 patients (27.3%) with triple-negative breast cancer (TNBC), and 1 patient (2.3%) with HR + /HER2 + disease. Patients had a median age of 56 years (range 33-82 years), 1 prior line of hormone therapy (range 0-6), and 2 prior lines of chemotherapy (range 0-7). CBR was 79.5% (35/44; 7 partial response, 28 stable disease) and the median DOR was 16.4 weeks (range 13.8-21.1 weeks). Median PFS was 16.4 weeks (95% CI: 13.8-21.1 weeks). The most common grade 3/4 adverse event was neutropenia (47.7%, n = 21). Fourteen of 26 patients (53.8%) with circulating tumor cell (CTC) data were CTC-positive ([Formula: see text] 5 CTC/7.5 mL) at baseline. Median PFS was shorter in patients who were CTC-positive vs. negative (13.1 vs 30.6 weeks, p = 0.011). CONCLUSION: In heavily pretreated patients with ABC, treatment with EC resulted in an encouraging CBR of 79.5% and PFS of 16.4 weeks, which compares favorably to single-agent eribulin. Dose reduction and delays were primarily due to neutropenia. The contribution of cyclophosphamide to eribulin remains unclear but warrants further evaluation. NCT01554371.
- Published
- 2024
23. Low prevalence of 'Schistosoma mekongi' infection and high prevalence of other helminth infections among domestic animals in Southern lao people's democratic republic
- Author
-
Sayasone, Somphou, Khattignavong, Phonepadith, Keomalaphet, Sengdeuane, Prasayasith, Phoyphaylinh, Soundala, Pheovaly, Sannikone, Sonesimmaly, Kumagai, Takashi, Phomhaksa, Souk, Inthavong, Phouth, Matsumoto-Takahashi, Emilie Louise Akiko, Hongvanthong, Bouasy, Brey, Paul T, Kano, Shigeyuki, and Iwagami, Moritoshi
- Published
- 2023
24. IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
- Author
-
Zhao Chong, Professor
- Published
- 2024
25. Colorectal Cancer Dataset in Xijing Hospital From 2011
- Published
- 2024
26. Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA (PTST_PALBEVA)
- Author
-
Haykel Hospital and Nehman Makdissy, Principal Investigator, Professor
- Published
- 2024
27. A Home-based Lifestyle Intervention for Optimizing Surgical Outcomes Among Urinary Bladder Cancer Patients (BOOST)
- Author
-
Mary Playdon, Assistant Professor (Nutrition & Integrative Physiology)
- Published
- 2024
28. Application of Douyin in Patients With Bone and Soft Tissue Malignant Tumors During Perichemotherapy
- Author
-
Wang Jiaqiang, associate chief physician
- Published
- 2024
29. Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients
- Published
- 2024
30. Biomarkers in Multiple Myeloma (VESICOM)
- Published
- 2024
31. The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer
- Author
-
Jihui Hao, Professor
- Published
- 2024
32. Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy
- Author
-
Xinxin Wang, Prof.
- Published
- 2024
33. Virtual Reality on Pain, Stress, and Affect in the Infusion Clinic
- Author
-
Cody Stansel, Principal Investigator
- Published
- 2024
34. Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer (XHZL)
- Author
-
Tao Zhang, Chief of Gastrointestinal Oncology Department
- Published
- 2024
35. Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC
- Published
- 2024
36. Subcutaneous administration of a novel TRPM8 antagonist reverses cold hypersensitivity while attenuating the drop in core body temperature.
- Author
-
Gold, Michael S., Pineda‐Farias, Jorge B., Close, David, Patel, Smith, Johnston, Paul A., Stocker, Sean D., and Journigan, V. Blair
- Subjects
- *
CANCER chemotherapy , *NEURALGIA , *BODY temperature , *TREATMENT effectiveness , *TRPV cation channels - Abstract
Background and Purpose: We extend the characterization of the TRPM8 antagonist VBJ103 with tests of selectivity, specificity and distribution, therapeutic efficacy of systemic administration against oxaliplatin‐induced cold hyperalgesia and the impact of systemic administration on core body temperature (CBT). Experimental Approach: Selectivity at human TRPA1 and TRPV1 as well as in vitro safety profiling was determined. Effects of systemic administration of VBJ103 were evaluated in a model of oxaliplatin‐induced cold hyperalgesia. Both peripheral and centrally mediated effects of VBJ103 on CBT were assessed with radiotelemetry. Key Results: VBJ103 had no antagonist activity at TRPV1 and TRPA1, but low potency TRPA1 activation. The only safety liability detected was partial inhibition of the dopamine transporter (DAT). VBJ103 delivered subcutaneously dose‐dependently attenuated cold hypersensitivity in oxaliplatin‐treated mice at 3, 10 and 30 mg·kg−1 (n = 7, P < 0.05). VBJ103 (30 mg·kg−1) antinociception was influenced by neither the TRPA1 antagonist HC‐030031 nor the DAT antagonist GBR12909. Subcutaneous administration of VBJ103 (3, 10 and 30 mg·kg−1, but not 100 or 300 mg·kg−1, n = 7) decreased CBT (2°C). Intraperitoneal (i.p.) administration of VBJ103 (3, 10 and 30 mg·kg−1) dose‐dependently decreased CBT to an extent larger than that detected with subcutaneous administration. Intracerebroventricular (i.c.v.) administration (306 nmol/1 μL; n = 5) did not alter CBT. Conclusions and Implications: We achieve therapeutic efficacy with subcutaneous administration of a novel TRPM8 antagonist that attenuates deleterious influences on CBT, a side effect that has largely prevented the translation of TRPM8 as a target. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Measurement of changes in serum-based inflammatory indicators to monitor response to nivolumab monotherapy in advanced gastric cancer: a multicenter retrospective study.
- Author
-
Inukai, Michiko, Nishi, Tomohiko, Matsuoka, Hiroshi, Matsuo, Kazuhiro, Suzuki, Kazumitsu, Serizawa, Akiko, Akimoto, Shingo, Nakauchi, Masaya, Tanaka, Tsuyoshi, Kikuchi, Kenji, Shibasaki, Susumu, Uyama, Ichiro, and Suda, Koichi
- Abstract
Background: Nonresectable gastric cancer develops rapidly; thus, monitoring disease progression especially in patients receiving nivolumab as late-line therapy is important. Biomarkers may facilitate the evaluation of nivolumab treatment response. Herein, we assessed the utility of serum-based inflammatory indicators for evaluating tumor response to nivolumab. Methods: This multicenter retrospective cohort study included 111 patients treated with nivolumab monotherapy for nonresectable advanced or recurrent gastric cancer from October 2017 to October 2021. We measured changes in the C-reactive protein (CRP)-to-albumin ratio (CAR), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR) in serum from baseline to after the fourth administration of nivolumab. Furthermore, we calculated the area under the receiver operating characteristic curves (AUC ROCs) for CAR, PLR, and NLR to identify the optimal cutoff values for treatment response. We also investigated the relationship between clinicopathologic factors and disease control (complete response, partial response, and stable disease) using the chi-squared test. Results: The overall response rate (complete and partial response) was 11.7%, and the disease control rate was 44.1%. The median overall survival (OS) was 14.0 (95% CI 10.7‒19.2) months, and the median progression-free survival (PFS) was 4.1 (95% CI 3.0‒5.9) months. The AUC ROCs for CAR, PLR, and NLR before nivolumab monotherapy for patients with progressive disease (PD) were 0.574 (95% CI, 0.461‒0.687), 0.528 (95% CI, 0.418‒0.637), and 0.511 (95% CI, 0.401‒0.620), respectively. The values for changes in CAR, PLR, and NLR were 0.766 (95% CI, 0.666‒0.865), 0.707 (95% CI, 0.607‒0.807), and 0.660 (95% CI 0.556‒0.765), respectively. The cutoff values for the treatment response were 3.0, 1.3, and 1.4 for CAR, PLR, and NLR, respectively. The PFS and OS were significantly longer when the treatment response values for changes in CAR, PLR, and NLR were below these cutoff values (CAR: OS, p < 0.0001 and PFS, p < 0.0001; PLR: OS, p = 0.0289 and PFS, p = 0.0302; and NLR: OS, p = 0.0077 and PFS, p = 0.0044). Conclusions: Measurement of the changes in CAR, PLR, and NLR could provide a simple, prompt, noninvasive method to evaluate response to nivolumab monotherapy. Trial registration: This study is registered with number K2023006. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Induction prior to autologous haematopoietic cell transplantation in multiple myeloma.
- Author
-
Mohty, Mohamad and Malard, Florent
- Abstract
Induction chemotherapy followed by autologous haematopoietic cell transplantation and post‐transplant therapy (including maintenance therapy with or without prior consolidation) is still considered as the standard of care for newly diagnosed young and fit multiple myeloma patients. Over the last years, superiority of quadruplet regimens for induction was established, with the addition of an anti‐CD38 monoclonal antibody to triplet regimen including a proteasome inhibitor, an IMiD (thalidomide or lenalidomide) or cyclophosphamide, and dexamethasone. Given quadruplet induction regimens are associated with deep response, including a high‐rate of sustained measurable residual disease negativity in a significant proportion of patients, they are now recommended for induction chemotherapy when available. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. DNA damage response-related ncRNAs as regulators of therapy resistance in cancer.
- Author
-
Ziru Gao, Xinchi Luan, Xuezhe Wang, Tianyue Han, Xiaoyuan Li, Zeyang Li, Peifeng Li, and Zhixia Zhou
- Abstract
The DNA damage repair (DDR) pathway is a complex signaling cascade that can sense DNA damage and trigger cellular responses to DNA damage to maintain genome stability and integrity. A typical hallmark of cancer is genomic instability or nonintegrity, which is closely related to the accumulation of DNA damage within cancer cells. The treatment principles of radiotherapy and chemotherapy for cancer are based on their cytotoxic effects on DNA damage, which are accompanied by severe and unnecessary side effects on normal tissues, including dysregulation of the DDR and induced therapeutic tolerance. As a driving factor for oncogenes or tumor suppressor genes, noncoding RNA (ncRNA) have been shown to play an important role in cancer cell resistance to radiotherapy and chemotherapy. Recently, it has been found that ncRNA can regulate tumor treatment tolerance by altering the DDR induced by radiotherapy or chemotherapy in cancer cells, indicating that ncRNA are potential regulatory factors targeting the DDR to reverse tumor treatment tolerance. This review provides an overview of the basic information and functions of the DDR and ncRNAs in the tolerance or sensitivity of tumors to chemotherapy and radiation therapy. We focused on the impact of ncRNA (mainly microRNA [miRNA], long noncoding RNA [lncRNA], and circular RNA [circRNA]) on cancer treatment by regulating the DDR and the underlying molecular mechanisms of their effects. These findings provide a theoretical basis and new insights for tumor-targeted therapy and the development of novel drugs targeting the DDR or ncRNAs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Treatment Outcomes in Patients with Recurrent Adrenocortical Carcinoma.
- Author
-
Dojcinovic, Tamara, Tomsic, Karin Zibar, Vodanovic, Ivana Dora, Dusek, Tina, Kraljevic, Ivana, Nekic, Anja Barac, Polovina, Tanja Skoric, Knezevic, Nikola, Alduk, Ana Marija, Golubic, Zrna Antunac, and Kastelan, Darko
- Subjects
- *
DISEASE relapse , *TREATMENT effectiveness , *SURGICAL excision , *DISEASE progression , *METASTASIS - Abstract
BackgroundMethodsResultsConclusionWhile numerous studies have explored treatment outcomes for the overall ACC patient cohort, data on the subpopulation of patients with recurrent disease are limited. Therefore, the aim of this study was to assess treatment outcomes in patients with recurrent ACC.In this retrospective study, we included 18 patients median age 49 years (42–62); 67% female) diagnosed with recurrent ENSAT stage I-III ACC who underwent either R0 (
n = 16) or Rx (n = 2) surgical resection of the tumor.The median time from the initial surgery to ACC recurrence was 29 months (IQR 18–50). Seven patients (39%) manifested local recurrence, while 11 patients (61%) developed distant metastases. The median follow-up duration after tumor recurrence was 32 months (IQR 25–53). Regarding the treatment of ACC recurrence, 10 patients underwent a second surgery either as an alone procedure (n = 4), or in combination with mitotane (n = 4), mitotane and chemotherapy (n = 1), or mitotane combined with radiotherapy (n = 1). The remaining patients received treatment involving chemotherapy±mitotane (n = 4) and locoregional therapy ±chemotherapy (n = 3). One patient chose not to proceed with further management and follow-up. The median PFS was 17 (95% CI 8–26) months while the median OS was not reached. In the multivariate model, increased mortality was associated with advanced age (p = 0.04) and a shorter interval to ACC recurrence (p = 0.03).A significant proportion of patients with ACC recurrence experience disease progression or second recurrence, despite all treatment efforts. Nevertheless, by integrating diverse treatment modalities, many patients have the potential to attain long-term survival. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
41. Genetic polymorphisms and platinum-induced hematological toxicity: a systematic review.
- Author
-
Yi Zheng, Mimi Tang, Zheng Deng, and Pei Cai
- Abstract
Background: Platinum-based chemotherapy bring severe hematological toxicity that can lead to dose reduction or discontinuation of therapy. Genetic variations have been reported to influence the risk and extent of hematological toxicity; however, the results are controversial and a comprehensive overview is lacking. This systematic review aimed to identify genetic biomarkers of platinum-induced hematological toxicity. Method: Pubmed, Embase and Web of science database were systematically reviewed for studies that evaluated the association of genetic variants and platinum-related hematological toxicity in tumor patients with no prior history of chemotherapy or radiation, published from inception to the 28th of January 2022. The studies should have specific toxicity scoring system as well as defined toxicity end-point. The quality of reporting was assessed using the Strengthening the Reporting of Genetic Association Studies (STREGA) checklist. Results were summarized using narrative synthesis. Results: 83 studies were eligible with over 682 single-nucleotide polymorphisms across 110 genes. The results are inconsistent and diverse with methodological issues including insufficient sample size, population stratification, various treatment schedule and toxicity end-point, and inappropriate statistics. 11 SNPs from 10 genes (ABCB1 rs1128503, GSTP1 rs1695, GSTM1 gene deletion, ERCC1 rs11615, ERCC1 rs3212986, ERCC2 rs238406, XPC rs2228001, XPCC1 rs25487, MTHFR rs1801133, MDM2 rs2279744, TP53 rs1042522) had consistent results in more than two independent populations. Among them, GSTP1 rs1695, ERCC1 rs11615, ERCC1 rs3212986, and XRCC1 rs25487 present the most promising results. Conclusion: Even though the results are inconsistent and severalmethodological concerns exist, this systematic review identified several genetic variations that deserve validation in well-defined studies with larger sample size and robust methodology. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. The hepatorenal protective effects of silymarin in cancer patients receiving chemotherapy: a randomized, placebo-controlled trial.
- Author
-
Erfanian, Safoora Sadat, Ansari, Hourieh, Javanmard, Shaghayegh Haghjooy, Amini, Zahra, and Hajigholami, Ali
- Subjects
THERAPEUTIC use of antineoplastic agents ,REPEATED measures design ,PLACEBOS ,CREATININE ,DATA analysis ,RESEARCH funding ,FLAVONOIDS ,BREAST tumors ,STATISTICAL sampling ,COMPUTED tomography ,ASPARTATE aminotransferase ,ANTINEOPLASTIC agents ,RANDOMIZED controlled trials ,CANCER patients ,ALKALINE phosphatase ,BILIRUBIN ,BLOOD urea nitrogen ,CHI-squared test ,MULTIVARIATE analysis ,DESCRIPTIVE statistics ,CANCER chemotherapy ,LONGITUDINAL method ,CONTROL groups ,PRE-tests & post-tests ,DRUG efficacy ,ALANINE aminotransferase ,ONE-way analysis of variance ,STATISTICS ,ANALYSIS of variance ,LIVER ,CLINICS ,COMPARATIVE studies ,DATA analysis software ,KIDNEYS ,DIETARY supplements ,EVALUATION - Abstract
Background: Breast cancer is one of the most common diseases globally that may have side effects on liver and renal function. Pharmacological treatments to reduce adverse liver and renal effects are still limited. It has been proposed that silymarin may possess hepatoprotective and anti-inflammatory properties. The present trial aims to assess the hepatorenal protective efficacy of silymarin supplementation in cancer patients receiving chemotherapy in an outpatient setting. Method: This is a randomized, placebo-controlled clinical trial that recruited female breast cancer patients. Participants were randomly assigned to one placebo group and two intervention groups. The control group received 140 mg of placebo daily, while the two intervention groups received 140 mg silymarin daily. Follow-up assessments were conducted at baseline, 3 weeks, and 6 weeks. At the beginning of the study, the patients were subjected to a computed tomography (CT) scan, and the liver and renal parameters such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), bilirubin, Blood urea nitrogen (BUN) and Creatinine (Cr) were examined through laboratory tests. Results: Despite two deaths and three dropouts, 100 patients completed the study. Silymarin showed significant effects on liver enzymes in the levels of ALP and bilirubin (P < 0.05), with no significant impact on renal function in the levels of Blood urea nitrogen (BUN) and Creatinine (Cr) (P > 0.05). The medication was well-tolerated, with minimal reported side effects (P > 0.05). Discussion: The study suggests that silymarin may have hepato-renal protective potential in breast cancer patients and improve patient tolerance to chemotherapy. The data presented on the efficacy and safety of silymarin may provide stronger foundation for further trials and for a possible use in clinical practice. Trial registration information: Registration Number: IRCT20201123049474N2, First Trial Registration: 16/08/2021, Access: https://www.irct.behdasht.gov.ir/trial/57641 [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Predictive value of peri-chemotherapy hematological parameters for febrile neutropenia in patients with cancer.
- Author
-
Hongyuan Jia, Long Liang, Xue Chen, Wenzhong Zha, Wei Diao, and Wei Zhang
- Subjects
BLOOD cell count ,LYMPHOCYTE count ,CANCER hospitals ,RECEIVER operating characteristic curves ,PREDICTION models ,FEBRILE neutropenia - Abstract
Objective: The aim of this study was to compare hematological parameters preand early post-chemotherapy, and evaluate their values for predicting febrile neutropenia (FN). Methods: Patients diagnosed with malignant solid tumors receiving chemotherapy were included. Blood cell counts peri-chemotherapy and clinical information were retrieved from the hospital information system. We used the least absolute shrinkage and selection operator (LASSO) method for variable selection and fitted selected variables to a logistic model. We assessed the performance of the prediction model by the area under the ROC curve. Results: The study population consisted of 4,130 patients with common solid tumors receiving a three-week chemotherapy regimen in Sichuan Cancer Hospital from February 2019 to March 2022. In the FN group, change percentage of neutrophil count decreased less (-0.02, CI: -0.88 to 3.48 vs. -0.04, CI: -0.83 to 2.24). Among hematological parameters, lower postchemotherapy lymphocyte count (OR 0.942, CI: 0.934-0.949), change percentage of platelet (OR 0.965, CI: 0.955-0.975) and higher change percentage of post-chemotherapy neutrophil count (OR 1.015, CI: 1.011- 1.018), and pre-chemotherapy NLR (OR 1.002, CI: 1.002-1.002) predicted an increased risk of FN. These factors improved the predicting model based on clinical factors alone. The AUC of the combination model was 0.8275. Conclusion: Peri-chemotherapy hematological markers improve the prediction of FN. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Practical Nomograms and Risk Stratification System for Predicting the Overall and Cancer-specific Survival in Patients with Anaplastic Astrocytoma.
- Author
-
Mei, Qing, Shen, Hui, Chai, Xubin, Jiang, Yuanfeng, and Liu, Jiachun
- Abstract
Anaplastic astrocytoma (AA) is an uncommon primary brain tumor with highly variable clinical outcomes. Our study aimed to develop practical tools for clinical decision-making in a population-based cohort study. Data from 2997 patients diagnosed with AA between 2004 and 2015 were retrospectively extracted from the Surveillance, Epidemiology, and End Results database. The Least Absolute Shrinkage and Selection Operator and multivariate Cox regression analyses were applied to select factors and establish prognostic nomograms. The discriminatory ability of these nomogram models was evaluated using the concordance index and receiver operating characteristic curve. Risk stratifications were established based on the nomograms. Selected 2997 AA patients were distributed into the training cohort (70%, 2097) and the validation cohort (30%, 900). Age, household income, tumor site, extension, surgery, radiotherapy, and chemotherapy were identified as independent prognostic factors for both overall survival (OS) and cancer-specific survival (CSS). In the training cohort, our nomograms for OS and CSS exhibited good predictive accuracy with concordance index values of 0.752 (95% CI: 0.741–0.764) and 0.753 (95% CI: 0.741–0.765), respectively. Calibration and decision curve analyses curves showed that the nomograms demonstrated considerable consistency and satisfactory clinical utilities. With the establishment of nomograms, we stratified AA patients into high- and low-risk groups, and constructed risk stratification systems for OS and CSS. We constructed two predictive nomograms and risk classification systems to effectively predict the OS and CSS rates in AA patients. These models were internally validated with considerable accuracy and reliability and might be helpful in future clinical practices. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Nucleus-targeting Oxaplatin(IV) prodrug Amphiphile for enhanced chemotherapy and immunotherapy.
- Author
-
Wei, Dengshuai, Yan, Jianqin, Cao, Zheng, Han, Shangcong, and Sun, Yong
- Abstract
Platinum(II)-based drugs (PtII), which hinder DNA replication, are the most widely used chemotherapeutics. However, current PtII drugs often miss their DNA targets, leading to severe side effects and drug resistance. To overcome this challenge, we developed a oxaliplatin-based platinum(IV) (PtIV) prodrug amphiphile (C 16 -OPtIV-R 8 K), integrating a long-chain hydrophobic lipid and a nucleus-targeting hydrophilic peptide (R 8 K). This design allows the prodrug to self-assemble into highly uniform lipid nanoparticles (NTPtIV) for enhanced targeting chemotherapy and immunotherapy. Subsequently, NTPtIV's bioactivity and effects were examined at diverse levels, encompassing cancer cells, 3D tumor spheres, and in vivo. Our in vitro studies show a 74% cancer cell nucleus localization of platinum drugs-3.6 times higher than that of oxaliplatin, achieving more than a ten-fold increase in eliminating drug-resistant cancer cells. In vivo , NTPtIV shows efficient tumor accumulation, leading to suppressed tumor growth of murine breast cancer. Moreover, NTPtIV recruited more CD4+ and CD8+ T cells and reduced CD4+ Foxp3+ Tregs to synergistically enhance targeted chemotherapy and immunotherapy. Overall, this strategy presents a promising advancement in nucleus-targeted cancer therapy, synergistically boosting the efficacy of chemotherapy and immunotherapy. Nucleus-targeted Pt lipid nanoparticles (NTPtIV) assembled by amphipathic PtIV prodrug (C 16 -OPtIV-R 8 K) with 74% efficiency to enable accumulation of Pt drugs in the cancerous nucleus for enhanced targeted chemotherapy and immunotherapy. [Display omitted] • A novel PtIV prodrug amphiphile (C 16 -OPtIV-R 8 K) for nucleus-targeting. • Nano-assembly nucleus-targeted PtIV lipid nanoparticles NTPtIV with 74% efficiency was obtained. • NTPtIV improves the endocytosis and nuclear targeting efficiency of Pt via lipidation and R 8 K. • NTPtIV induces cancer cell death and reverses Pt-based drug resistance for targeted chemotherapy and enhanced immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Evaluation of early fluoropyrimidine toxicity in solid organ cancer patients: a retrospective observational study in Australia.
- Author
-
White, Cassandra, Kendall, Guy, Millington, Tegan, Corcoran, Bern, Paul, Christine, Scott, Rodney J., and Ackland, Stephen
- Subjects
- *
NAUSEA , *VOMITING , *DIARRHEA , *FEBRILE neutropenia , *AUDITING , *ANTIMETABOLITES , *ANTINEOPLASTIC agents , *RETROSPECTIVE studies , *CANCER patients , *LONGITUDINAL method , *MEDICAL records , *ACQUISITION of data , *FLUOROURACIL , *DISEASE risk factors ,RISK factors - Abstract
Background: Despite common global usage, fluoropyrimidine (FP; 5‐flurouracil and capecitabine)‐related chemotherapy toxicity is poorly reported in the literature, with serious toxicity ranging from 10% to 40% and early toxicity (within 60 days of exposure) quoted at 14%. Data reflecting the incidence of Grades 3–5 FP‐related toxicity in Australian cancer patients is scant, despite the significant impact of toxicity on patients (hospitalisations, intensive care unit (ICU) admissions and even death). Aims: This retrospective audit evaluated Grades 3–5 toxicities in a contemporaneous cohort of 500 patients receiving FP chemotherapies within the Hunter‐New England Local Health District from June 2020 to June 2022. Data were extracted from public hospital records and oncology‐specific e‐records to determine rates of toxicity and associated hospitalisations, intensive care admissions and deaths that occurred within 60 days of first exposure to FP chemotherapy‐containing regimens. Results: One hundred and fifty incidents of Grades 3–4 toxicity in the first 60 days led to 87 patients presenting to hospital (87/500, 17.4%). The most common serious toxicities were diarrhoea (39.3%), nausea and vomiting (22.7%) and febrile neutropaenia (10%). Four patients were admitted to the ICU, and four patients died of toxicity. Within the first 60 days, 22.2% of patients required treatment delays, 21.4% required dose reductions, and 7.8% of patients ceased treatment because of toxicities. Discussion and Conclusion: Our experience reflects international reports and is likely generalisable to the Australian population. These data are a basis to understand the potential benefits of precision medicine strategies such as pharmacogenomic screening to improve patient tolerability and the cost‐effectiveness of FP chemotherapy prescribing. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Ovarian microenvironment: challenges and opportunities in protecting against chemotherapy-associated ovarian damage.
- Author
-
Guo, Yican, Xue, Liru, Tang, Weicheng, Xiong, Jiaqiang, Chen, Dan, Dai, Yun, Wu, Chuqing, Wei, Simin, Dai, Jun, Wu, Meng, and Wang, Shixuan
- Abstract
BACKGROUND Chemotherapy-associated ovarian damage (CAOD) is one of the most feared short- and long-term side effects of anticancer treatment in premenopausal women. Accumulating detailed data show that different chemotherapy regimens can lead to disturbance of ovarian hormone levels, reduced or lost fertility, and an increased risk of early menopause. Previous studies have often focused on the direct effects of chemotherapeutic drugs on ovarian follicles, such as direct DNA damage-mediated apoptotic death and primordial follicle burnout. Emerging evidence has revealed an imbalance in the ovarian microenvironment during chemotherapy. The ovarian microenvironment provides nutritional support and transportation of signals that stimulate the growth and development of follicles, ovulation, and corpus luteum formation. The close interaction between the ovarian microenvironment and follicles can determine ovarian function. Therefore, designing novel and precise strategies to manipulate the ovarian microenvironment may be a new strategy to protect ovarian function during chemotherapy. OBJECTIVE AND RATIONALE This review details the changes that occur in the ovarian microenvironment during chemotherapy and emphasizes the importance of developing new therapeutics that protect ovarian function by targeting the ovarian microenvironment during chemotherapy. SEARCH METHODS A comprehensive review of the literature was performed by searching PubMed up to April 2024. Search terms included 'ovarian microenvironment' (ovarian extracellular matrix, ovarian stromal cells, ovarian interstitial, ovarian blood vessels, ovarian lymphatic vessels, ovarian macrophages, ovarian lymphocytes, ovarian immune cytokines, ovarian oxidative stress, ovarian reactive oxygen species, ovarian senescence cells, ovarian senescence-associated secretory phenotypes, ovarian oogonial stem cells, ovarian stem cells), terms related to ovarian function (reproductive health, fertility, infertility, fecundity, ovarian reserve, ovarian function, menopause, decreased ovarian reserve, premature ovarian insufficiency/failure), and terms related to chemotherapy (cyclophosphamide, lfosfamide, chlormethine, chlorambucil, busulfan, melphalan, procarbazine, cisplatin, doxorubicin, carboplatin, taxane, paclitaxel, docetaxel, 5-fluorouraci, vincristine, methotrexate, dactinomycin, bleomycin, mercaptopurine). OUTCOMES The ovarian microenvironment shows great changes during chemotherapy, inducing extracellular matrix deposition and stromal fibrosis, angiogenesis disorders, immune microenvironment disturbance, oxidative stress imbalances, ovarian stem cell exhaustion, and cell senescence, thereby lowering the quantity and quality of ovarian follicles. Several methods targeting the ovarian microenvironment have been adopted to prevent and treat CAOD, such as stem cell therapy and the use of free radical scavengers, senolytherapies, immunomodulators, and proangiogenic factors. WIDER IMPLICATIONS Ovarian function is determined by its 'seeds' (follicles) and 'soil' (ovarian microenvironment). The ovarian microenvironment has been reported to play a vital role in CAOD and targeting the ovarian microenvironment may present potential therapeutic approaches for CAOD. However, the relation between the ovarian microenvironment, its regulatory networks, and CAOD needs to be further studied. A better understanding of these issues could be helpful in explaining the pathogenesis of CAOD and creating innovative strategies for counteracting the effects exerted on ovarian function. Our aim is that this narrative review of CAOD will stimulate more research in this important field. REGISTRATION NUMBER Not applicable. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study.
- Author
-
Doshita, Kosei, Naito, Tateaki, Matsuda, Suguru, Morita, Meiko, Sekikawa, Motoki, Miura, Keita, Kodama, Hiroaki, Yabe, Michitoshi, Morikawa, Noboru, Iida, Yuko, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Murakami, Haruyasu, Kenmotsu, Hirotsugu, and Takahashi, Toshiaki
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *ANOREXIA nervosa treatment , *CANCER relapse , *ANTINEOPLASTIC agents , *TREATMENT effectiveness , *RETROSPECTIVE studies , *CANCER patients , *LUNGS , *DESCRIPTIVE statistics , *IMMUNE checkpoint inhibitors , *CANCER chemotherapy , *LUNG tumors , *ANOREXIA nervosa , *MEDICAL records , *ACQUISITION of data , *LUNG cancer , *PROGRESSION-free survival , *COMPARATIVE studies , *OVERALL survival , *PLATINUM , *DISEASE complications - Abstract
Background: Chemotherapy‐induced anorexia is a common occurrence in patients undergoing treatment for advanced lung cancer. However, the relationship between chemotherapy‐induced anorexia and weight loss during platinum‐based chemotherapy combined with immune checkpoint inhibitors is unclear. This study explored the relationship between chemotherapy‐induced anorexia and therapeutic outcomes in patients with stage IV non‐small‐cell lung cancer undergoing platinum‐based chemotherapy combined with immune checkpoint inhibitors. Methods: The study retrospectively reviewed the medical records of 106 patients with stage IV non‐small‐cell lung cancer treated with platinum‐based chemotherapy and immune checkpoint inhibitors between January 2019 and October 2022. The incidence of weight loss and its association with treatment efficacy was assessed in the chemotherapy‐induced anorexia group. Chemotherapy‐induced anorexia, nausea, and vomiting were evaluated using Common Terminology Criteria for Adverse Events v 5.0. Progression‐free and overall survival were used to measure treatment efficacy. Results: Chemotherapy‐induced anorexia was observed in 13.2% of patients. These patients exhibited significant weight loss at 6 and 9 weeks after treatment initiation compared to those in the non‐chemotherapy‐induced anorexia group. Progression‐free and overall survival were shorter in the chemotherapy‐induced anorexia group than in the non‐chemotherapy‐induced anorexia group, but the difference was not statistically significant. Conclusions: Chemotherapy‐induced anorexia was associated with significant weight loss and reduced treatment efficacy in patients with stage IV non‐small‐cell lung cancer. These results highlight the importance of implementing robust supportive care for chemotherapy‐induced anorexia to mitigate weight loss and uphold treatment effectiveness during platinum‐based chemotherapy combined with immune checkpoint inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Chemotherapy-induced peripheral neuropathy models constructed from human induced pluripotent stem cells and directly converted cells: a systematic review.
- Author
-
Smulders, Pascal S. H., Heikamp, Kim, Hermanides, Jeroen, Hollmann, Markus W., ten Hoope, Werner, and Weber, Nina C.
- Abstract
Developments in human cellular reprogramming now allow for the generation of human neurons for in vitro disease modelling. This technique has since been used for chemotherapy-induced peripheral neuropathy (CIPN) research, resulting in the description of numerous CIPN models constructed from human neurons. This systematic review provides a critical analysis of available models and their methodological considerations (ie, used cell type and source, CIPN induction strategy, and validation method) for prospective researchers aiming to incorporate human in vitro models of CIPN in their research. The search strategy was developed with assistance from a clinical librarian and conducted in MEDLINE (PubMed) and Embase (Ovid) on September 26,2023. Twenty-six peer-reviewed experimental studies presenting original data about human reprogrammed nonmotor neuron cell culture systems and relevant market available chemotherapeutics drugs were included. Virtually, all recent reports modeled CIPN using nociceptive dorsal root ganglion neurons. Drugs known to cause the highest incidence of CIPN were most used. Furthermore, treatment effects were almost exclusively validated by the acute effects of chemotherapeutics on neurite dynamics and cytotoxicity parameters, enabling the extrapolation of the half-maximal inhibitory concentration for the 4 most used chemotherapeutics. Overall, substantial heterogeneity was observed in the way studies applied chemotherapy and reported their findings. We therefore propose 6 suggestions to improve the clinical relevance and appropriateness of human cellular reprogramming-derived CIPN models. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Association between salivary inflammatory mediators and oral mucositis in patients with cancer undergoing chemotherapy.
- Author
-
Yoshida, Kensuke, Kiyomi, Anna, Kurokawa, Akira, Hoshino, Naoto, Saito, Chie, Koga, Masayoshi, Oonuki, Mai, Kanemaru, Hiroko, Pak, Kyongsun, Tomihara, Kei, and Sugiura, Munetoshi
- Abstract
Purpose: Oral mucositis is a severe adverse event in patients undergoing chemotherapy and radiotherapy that may lead to the termination of cancer treatment. This study aimed to elucidate the relationship between salivary inflammatory mediators and oral mucositis in patients undergoing chemotherapy. Methods: This prospective cohort study included 167 patients who underwent chemotherapy at our institution between June 2020 and November 2023. We evaluated the association between chemotherapy-induced oral mucositis and salivary inflammatory mediators using multiple comparison tests and logistic regression analyses. Results: Of the 167 patients, 67 (40.1%) had oral mucositis. Dunn’s multiple comparison test revealed that interleukin-6 was significantly higher in oral mucositis of grades 2 and ≥ 3 (P < 0.01) and tumor necrosis factor (TNF)-α was significantly higher in oral mucositis of grades 3–4 (P < 0.01). Logistic regression analysis showed that the risk of oral mucositis was significantly higher for tumor necrosis factor (TNF)-α > 4.4 pg/mL than for TNF-α ≤ 4.4 pg/mL (adjusted odds ratio, 2.4; 95% confidence interval, 1.1–5.3; P = 0.03). Conclusion: Saliva is useful in evaluating inflammation in patients with chemotherapy-induced oral mucositis. Furthermore, TNF-α may be a predictive marker for the severity of oral mucositis in patients undergoing chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.